Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are characterized by differences in transmissibility and response to therapeutics. Therefore, discriminating among them is vital for surveillance, infection prevention, and patient care. While whole viral genome sequencing (WGS) is the “gold standard” for variant identification, molecular variant panels have become increasingly available. Most, however, are based on limited targets and have not undergone comprehensive evaluation. We assessed the diagnostic performance of the highly multiplexed Agena MassARRAY® SARS-CoV-2 Variant Panel v3 to identify variants in a diverse set of 391 SARS-CoV-2 clinical RNA specimens collected across our health systems in New York City, USA as well as in Bogotá, Colombia (September 2, 2020 – March 2, 2022). We demonstrate almost perfect levels of interrater agreement between this assay and WGS for 9 of 11 variant calls (κ ≥ 0.856) and 25 of 30 targets (κ ≥ 0.820) tested on the panel. The assay had a high diagnostic sensitivity (≥93.67%) for contemporary variants (e.g., Iota, Alpha, Delta, Omicron [BA.1 sublineage]) and a high diagnostic specificity for all 11 variants (≥96.15%) and all 30 targets (≥94.34%) tested. Moreover, we highlight distinct target patterns that can be utilized to identify variants not yet defined on the panel including the Omicron BA.2 and other sublineages. These findings exemplify the power of highly multiplexed diagnostic panels to accurately call variants and the potential for target result signatures to elucidate new ones.
Importance The continued circulation of SARS-CoV-2 amidst limited surveillance efforts and inconsistent vaccination of populations has resulted in emergence of variants that uniquely impact public health systems. Thus, in conjunction with functional and clinical studies, continuous detection and identification are quintessential to inform diagnostic and public health measures. Furthermore, until WGS becomes more accessible in the clinical microbiology laboratory, the ideal assay for identifying variants must be robust, provide high resolution, and be adaptable to the evolving nature of viruses like SARS-CoV-2. Here, we highlight the diagnostic capabilities of a highly multiplexed commercial assay to identify diverse SARS-CoV-2 lineages that circulated at over September 2, 2020 – March 2, 2022 among patients seeking care at our health systems. This assay demonstrates variant-specific signatures of nucleotide/amino acid polymorphisms and underscores its utility for detection of contemporary and emerging SARS-CoV-2 variants of concern.
Competing Interest Statement
Robert Sebra is VP of Technology Development and a stockholder at Sema4, a Mount Sinai Venture. This work, however, was conducted solely at Icahn School of Medicine at Mount Sinai. Otherwise, the authors declare no competing interests.
Funding Statement
This research was supported by the Center for Research on Influenza Pathogenesis, a National Institutes of Health (NIH) funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract number HHSN272201400008C; CEIRR contract number 75N93021C00014) [Icahn School of Medicine at Mount Sinai (ISMMS)], the NIH Office of Research Infrastructure under award numbers S10OD018522 and S10OD026880 [ISMMS Scientific Computing and Data, Patricia Kovatch], institutional and philanthropic funds (Open Philanthropy Project, #2020-215611 [ISMMS Department of Microbiology, Dr. Adolfo Garcia-Sastre, V.S. and H.v.B.], the Pershing Square Foundation [Mount Sinai Health System, Dr. David L. Reich and A.E.PM.], as well as a Robin Chemers Neustein Postdoctoral Fellowship Award [A.S.GR.]. We thank the Universidad del Rosario in the framework of its strategic plan RUTA2025. Thanks to President and the University Council for leading the strategic projects (JR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For specimens obtained through routine testing at MSHS, the Mount Sinai Pathogen Surveillance Program was reviewed and approved by the Human Research Protection Program at the Icahn School of Medicine at Mount Sinai (ISMMS) (HS#13-00981). For specimens from Colombia, the study was reviewed and approved by the ethics Committee from Universidad del Rosario in Bogota, Colombia (Act number DVO005 1550-CV1499). This study was performed following the Declaration of Helsinki and its later amendments, and all patient data was anonymized to minimize risk to participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Mount Sinai PSP Study Group (in alphabetical order): Hala Alshammary, Angela A. Amoako, Mahmoud H. Awawda, Christian Cognigni, Aria Rooker, Jose Polanco, Levy A. Sominsky, Komal Srivastava, Huanzhi Shi, Liyong Cao, Feng Chen, Jian Zhang, Zain Khalil
Data Availability
All single variant consensus genome sequences were deposited in the publicly-available Global Initiative on Sharing Avian Influenza Data (GISAID) database (www.gisaid.org) [accession identifiers indicated in Table S4]. The remaining 10 genomes with mixed patters of mutations were not deposited into GISAID as single variant consensus genomes could not be resolved (data available upon request).
